10-K: Zomedica Corp. Faces NYSE American Delisting Amidst Strategic Shifts and Financial Results

Zomedica Corp.'s 2024 10-K filing reveals a company in transition, navigating delisting from NYSE American while focusing on strategic acquisitions and product commercialization to drive future growth.

Summary

• Zomedica Corp., an animal health company, reported its 10-K filing for the year ended December 31, 2024.
• The company's shares were delisted from NYSE American due to non-compliance with listing standards related to low share price and began trading on the OTCQB market under the symbol ZOMDF.
• Zomedica is focused on commercializing six product lines, including diagnostic and therapeutic devices for companion animals.
• Revenue increased to $27.3 million in 2024 from $25.2 million in 2023, driven by growth in PulseVet and TRUFORMA products.
• The company incurred a net loss of $46.9 million in 2024, compared to a net loss of $33.6 million in 2023, primarily due to increased operating expenses and impairment charges.
• Zomedica is expanding its product portfolio through acquisitions, including Structured Monitoring Products, Inc. (SMP) and Qorvo Biotechnologies, LLC (QBT).
• The company is investing in research and development to expand its diagnostic and therapeutic device platforms.
• Zomedica is managing its manufacturing and distribution capabilities through facilities in Roswell, Georgia, and Plymouth, Minnesota.
• The company faces risks related to competition, supply chain disruptions, and regulatory changes.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there is revenue growth and strategic acquisitions, the increased net loss, delisting from NYSE American, and ongoing risks create a negative outlook.

Positives

• Revenue increased by 8% to $27.3 million in 2024, indicating growth in product sales.
• Gross profit margin increased to 70% in 2024 from 69% in 2023, reflecting improved cost management.
• The company expanded its product portfolio through strategic acquisitions of SMP and QBT.
• Zomedica launched new assays for its TRUFORMA product platform, including the first assays for equine diagnostics.
• The company has a strong intellectual property portfolio with numerous patents and trademarks.
• Zomedica is commercializing VETIGEL hemostatic gel, a fast-acting product that stops bleeding in seconds.

Negatives

• The company incurred a net loss of $46.9 million in 2024, indicating ongoing financial challenges.
• Zomedica's shares were delisted from NYSE American due to non-compliance with listing standards.
• The company recognized impairment charges of $16.0 million in 2024, reflecting a decline in the value of certain assets.
• Zomedica faces significant competition in the animal diagnostics and medical device markets.
• The company is subject to risks associated with public health crises, such as pandemics and epidemics.
• Zomedica may be required to make significant cash payments under its agreement with Brisby, which could impact liquidity.

Risks

• The company may never become profitable and may be unable to continue operations at planned levels.
• Zomedica faces unproven markets for its existing and future products.
• The company's existing and future products will face significant competition.
• Disruption in the global supply chain could increase costs and delay the ability to manufacture products.
• The company's strategic relationships are important to its business, and failure to maintain these relationships could adversely affect the business.
• Security breaches, loss of data, and other disruptions could compromise sensitive information and expose the company to liability.
• Various government regulations could limit or delay the ability to develop and commercialize products.
• The company's ability to obtain intellectual property protection for its products is limited.
• The price of the company's common shares will fluctuate substantially.
• The company may be required to make significant cash payments under its agreement with Brisby, which could impact liquidity.

Future Outlook

The company expects to continue incurring losses for the foreseeable future as it continues its integration efforts, product development, and commercialization activities, but anticipates that losses will begin to decrease from historical levels as it continues to rapidly grow its Therapeutic Device segment and continue the commercialization of its Diagnostic products.

Industry Context

The pet care industry is experiencing strong growth, driven by the humanization of pets and the premiumization of their care, with the global equine healthcare market also showing growth due to increased ownership of horses and improved animal health awareness.

Comparison to Industry Standards

• The document mentions key competitors in the diagnostic market such as Idexx Laboratories, Inc., Antech Diagnostics, Heska Corporation, Bionote USA Inc., and Zoetis Inc.
• In the shock-wave market, competitors include Companion Animal Health, K-Laser, Summus Medical Laser, LLC, ELvation Medical GmbH and Curative Sound.
• Assisi products face competition from Respond Systems Incorporated.
• The veterinary ultrasound equipment market is competitive, with companies such as Sound and Universal Imaging providing equipment options.
• The TRUVIEW platform competes with Zoetis Imagyst, Heskas Element AIM, and Idexx Digital Cytology inVue Dx platform.

Stakeholder Impact

• Shareholders are impacted by the delisting from NYSE American and the increased net loss.
• Employees are impacted by the company's restructuring actions and changes in compensation.
• Customers may benefit from the company's expanded product portfolio and improved services.
• Suppliers and creditors are impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• The company intends to leverage its infrastructure and commercial capability to continue to grow its existing products, launch new products complementary to its existing products, and acquire new products to market to veterinarians and pet parents.
• The company plans to increase market awareness of VETIGEL through targeted educational initiatives, including clinical demonstrations, case studies, and practitioner training programs.
• The company will continue to explore additional programs to accelerate uptake of PulseVet in the small animal market in 2025.

Key Dates